Last10K.com

Dandrit Biotech Usa, Inc. (DDRT) SEC Filing 10-K Annual report for the fiscal year ending Thursday, June 30, 2016

Dandrit Biotech Usa, Inc.

CIK: 1527728 Ticker: DDRT
Document and Entity Information - USD ($)
12 Months Ended
Jun. 30, 2016
Sep. 25, 2016
Dec. 31, 2015
Document and Entity Information [Abstract]   
Entity Registrant NameDanDrit Biotech USA, Inc.  
Entity Central Index Key0001527728  
Amendment Flagfalse  
Current Fiscal Year End Date--06-30  
Document Type10-K  
Document Period End DateJun. 30, 2016  
Document Fiscal Year Focus2016  
Document Fiscal Period FocusFY  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategorySmaller Reporting Company  
Entity Public Float  $ 32,509,226
Entity Common Stock Shares Outstanding 9,533,290 

View differences made from one year to another to evaluate Dandrit Biotech Usa, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dandrit Biotech Usa, Inc..

Continue

Assess how Dandrit Biotech Usa, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dandrit Biotech Usa, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Cash Flows
Consolidated Statement Of Operations
Consolidated Statement Of Stockholders' (deficit)
Consolidated Statement Of Stockholders' (deficit) (parenthetical)
Consolidated Statements Of Other Comprehensive Loss
Asset Purchase Agreement
Asset Purchase Agreement (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Definite-life Intangible Assets
Definite-life Intangible Assets (details Textual)
Definite-life Intangible Assets (details)
Definite-life Intangible Assets (tables)
Derivative Liabilities
Going Concern
Going Concern (details)
Income Taxes
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Leases
Leases (details)
Loss Per Share
Loss Per Share (details Textual)
Loss Per Share (details)
Loss Per Share (tables)
Notes Payable - Related Party
Notes Payable - Related Party (details 1)
Notes Payable - Related Party (details Textual)
Notes Payable - Related Party (details)
Notes Payable - Related Party (tables)
Property And Equipment
Property And Equipment (details Textual)
Property And Equipment (details)
Property And Equipment (tables)
Related Party Transactions
Related Party Transactions (details)
Stockholders' Equity
Stockholders' Equity (details)
Subsequent Event
Subsequent Event (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)

Material Contracts, Statements, Certifications & more

Dandrit Biotech Usa, Inc. provided additional information to their SEC Filing as exhibits

Ticker: DDRT
CIK: 1527728
Form Type: 10-K Annual Report
Accession Number: 0001213900-16-017105
Submitted to the SEC: Wed Sep 28 2016 5:21:46 PM EST
Accepted by the SEC: Wed Sep 28 2016
Period: Thursday, June 30, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ddrt/0001213900-16-017105.htm